TP53 and glioblastoma: SGT-53, a nanocomplex containing a normal human wt p53 cDNA, demonstrated excellent tolerability in the first human tests and was followed by a phase 1b combination trial that established the safety and therapeutic potential of SGT-53 when used in combination with docetaxel for the treatment of various solid tumors, including glioblastoma among others (Pirollo et al., 2016).